Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.

Published on RocksNews: 20 Oct 2026, 13:39 UTC
Updated: 20 Oct 2026, 13:39 UTC
Language: English

Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis — Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis — Image credit: CNBC – Top News

Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.

United Airlines slashes 2026 profit outlook on fuel prices, but travelers keep booking despite higher fares

20 Oct 2026, 20:46 UTC

OpenAI CEO Sam Altman wins dismissal of sister's lawsuit

20 Oct 2026, 20:40 UTC

We're booking big profits in an AI stock and trimming a credit-exposed bank

20 Oct 2026, 19:45 UTC

Boeing wins FAA approval for 737 Max 10 after years of delays

20 Oct 2026, 19:45 UTC

How First Class Jerk Is Building a Travel Media Brand

20 Oct 2026, 19:11 UTC

Stocks try for back-to-back gains — plus, Qnity gets iPhone business from Apple

20 Oct 2026, 18:44 UTC